To include your compound in the COVID-19 Resource Center, submit it here.

Allergan strikes dry eye deal with Mimetogen

Allergan plc (NYSE:AGN) reported 3Q15 earnings and licensed dry eye candidate tavilermide ( MIM-D3) from Mimetogen Pharmaceuticals Inc. (Montreal, Quebec). Allergan did not give an update regarding merger

Read the full 285 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE